Not Yet Recruiting INTERVENTIONAL NCT07561645

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung (ALPINE 2)

A Phase II, Single-arm Trial on the Addition of the DLL3xCD3 Bispecific T-cell Engager Obrixtamig (BI 764532) to Standard-of-care Platinum-based First-line Treatment of Advanced Large-cell Neuroendocrine Carcinoma of the Lung

Sponsor: Technische Universität Dresden

Conditions Large Cell Neuroendocrine Carcinoma of the Lung

Interventions Obrixtamig

Updated 1 time since 2026 Last updated: Apr 27, 2026 Started: Jul 1, 2026 Primary completion: Apr 1, 2032 Completion: Apr 1, 2032

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Large Cell Neuroendocrine Carcinoma of the Lung, this trial is actively recruiting participants. The trial is conducted by Technische Universität Dresden and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

1 version recorded

Not Yet Recruiting [daily]

Eligibility Summary

This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.

Contact Information

Sponsor contact:

Technische Universität Dresden

Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.